Conditions: Seasonal Allergic Rhinitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 345
Healthy volunteers: no

Brief summary:
The objectives of this study are to determine the safety and efficacy in seasonal allergic rhinitis of a four-week course of mometasone furoate compared to beclomethasone dipropionate or placebo.

Detailed description:

Arms:
arm 1: Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days. arm 2: Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days. arm 3: Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.

Interventions: intervention 1: Mometasone Furoate (MF) intervention 2: Beclomethasone Dipropionate (BDP) intervention 3: Placebo
Intervention descriptions: intervention 1: Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks. intervention 2: Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks. intervention 3: Placebo nasal spray administered for 4 weeks.

Protocol document: